Nitrofurantoin Alternova (Nitrofurantoin)

Nitrofurantoin is reduced by bacterial enzymes to reactive intermediates that damage bacterial DNA, disrupt carbohydrate metabolism, and interfere with cell‑wall synthesis. These actions selectively kill susceptible uropathogens in the urinary tract while sparing most human cells.

The appropriate dose and duration are determined by the prescribing healthcare professional based on the severity of infection, renal function, and individual patient factors. The prescriber will specify the exact regimen on the prescription label.

Safety data for nitrofurantoin in pregnancy are limited, and the drug is generally avoided near term because of potential fetal hemolysis. Caution is also advised during breastfeeding; the prescriber should evaluate risks and benefits before use.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for uncomplicated cystitis is trimethoprim‑sulfamethoxazole. Nitrofurantoin has a narrower spectrum focused on urinary pathogens and is less likely to cause systemic side effects, but it requires adequate renal function for efficacy. Choice depends on local resistance patterns and patient-specific factors.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and heat. Keep the container tightly closed and out of reach of children.

Nitrofurantoin Alternova is taken orally, usually with a full glass of water. It can be taken with food or after meals to lessen gastrointestinal discomfort, but patients should follow the specific instructions provided by their prescriber.

Serious adverse reactions include pulmonary toxicity (such as interstitial lung disease), hepatic injury (elevated liver enzymes or hepatitis), and hemolytic anemia, particularly in individuals with glucose‑6‑phosphate dehydrogenase deficiency. Any new respiratory, liver‑related, or hematologic symptoms should prompt immediate medical evaluation.

Contraindications include known hypersensitivity to nitrofurantoin or other nitrofurans, severe renal impairment (creatinine clearance <30 mL/min), G6PD deficiency due to risk of hemolysis, and late‑term pregnancy. Patients with a history of pulmonary or hepatic reactions to the drug should also avoid its use.